Total Payments
$5,774
2024 Payments
$293.91
Companies
37
Transactions
305
Medicare Patients
12,724
Medicare Billing
$942,182
Payment Breakdown by Category
Food & Beverage$5,635 (97.6%)
Education$138.70 (2.4%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $5,635 | 300 | 97.6% |
| Education | $138.70 | 5 | 2.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Janssen Pharmaceuticals, Inc | $591.98 | 28 | $0 (2023) |
| Novo Nordisk Inc | $501.75 | 17 | $0 (2021) |
| AstraZeneca Pharmaceuticals LP | $496.96 | 29 | $0 (2023) |
| AbbVie Inc. | $403.56 | 22 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $381.06 | 21 | $0 (2024) |
| Lilly USA, LLC | $350.80 | 16 | $0 (2024) |
| GlaxoSmithKline, LLC. | $349.75 | 20 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $341.96 | 13 | $0 (2019) |
| E.R. Squibb & Sons, L.L.C. | $321.20 | 18 | $0 (2023) |
| Supernus Pharmaceuticals, Inc. | $296.76 | 19 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $293.91 | 11 | Lilly USA, LLC ($101.24) |
| 2023 | $293.50 | 15 | AbbVie Inc. ($93.07) |
| 2022 | $485.45 | 26 | ABBVIE INC. ($171.37) |
| 2021 | $679.80 | 33 | AbbVie Inc. ($139.12) |
| 2020 | $575.17 | 34 | Janssen Pharmaceuticals, Inc ($82.57) |
| 2019 | $653.01 | 36 | Janssen Pharmaceuticals, Inc ($143.22) |
| 2018 | $1,577 | 75 | Novo Nordisk Inc ($307.91) |
| 2017 | $1,216 | 75 | Novartis Pharmaceuticals Corporation ($193.37) |
All Payment Transactions
305 individual payment records from CMS Open Payments — Page 1 of 13
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/03/2024 | Exact Sciences Corporation | Cologuard Collection Kit (Device) | Food and Beverage | In-kind items and services | $17.26 | General |
| Category: Oncology | ||||||
| 10/23/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $15.82 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/03/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug), AREXVY | Food and Beverage | In-kind items and services | $25.38 | General |
| Category: RESPIRATORY | ||||||
| 09/17/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $17.80 | General |
| Category: PSYCHIATRY | ||||||
| 08/28/2024 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | LifeVest (Device) | Food and Beverage | Cash or cash equivalent | $18.00 | General |
| Category: Electromedical and Electrotherapeutic Apparatus | ||||||
| 07/11/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug), TRELEGY ELLIPTA | Food and Beverage | In-kind items and services | $33.19 | General |
| Category: RESPIRATORY | ||||||
| 06/11/2024 | Alkermes, Inc. | ARISTADA (Drug), ARISTADA, ARISTADA | Food and Beverage | In-kind items and services | $15.51 | General |
| Category: CNS | ||||||
| 05/28/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | Cash or cash equivalent | $101.24 | General |
| Category: Diabetes | ||||||
| 05/22/2024 | Organon Llc | NEXPLANON (Drug) | Food and Beverage | In-kind items and services | $14.25 | General |
| Category: ETONOGESTREL | ||||||
| 03/06/2024 | Exact Sciences Corporation | Cologuard Collection Kit (Device) | Food and Beverage | In-kind items and services | $16.42 | General |
| Category: Oncology | ||||||
| 02/06/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $19.04 | General |
| Category: PSYCHIATRY | ||||||
| 12/07/2023 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $30.77 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 10/03/2023 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $19.30 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 09/12/2023 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $15.74 | General |
| Category: PSYCHIATRY | ||||||
| 09/08/2023 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $18.78 | General |
| Category: PSYCHIATRY | ||||||
| 08/07/2023 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug), SHINGRIX, AREXVY | Food and Beverage | In-kind items and services | $18.60 | General |
| Category: RESPIRATORY | ||||||
| 07/13/2023 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $21.13 | General |
| Category: PSYCHIATRY | ||||||
| 07/06/2023 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $21.32 | General |
| Category: NEUROSCIENCE | ||||||
| 06/21/2023 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $12.92 | General |
| Category: NEUROSCIENCE | ||||||
| 06/19/2023 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $14.40 | General |
| Category: Respiratory | ||||||
| 05/24/2023 | SANOFI PASTEUR INC. | FLUZONE QUADRIVALENT NORTHERN HEMISPHERE (Biological), FLUZONE HIGH-DOSE, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE | Food and Beverage | In-kind items and services | $20.16 | General |
| Category: Vaccines | ||||||
| 04/28/2023 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $25.86 | General |
| Category: NEUROSCIENCE | ||||||
| 03/15/2023 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $17.80 | General |
| Category: PSYCHIATRY | ||||||
| 03/10/2023 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $15.80 | General |
| Category: NEUROSCIENCE | ||||||
| 02/08/2023 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $23.75 | General |
| Category: Cardiovascular | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 32 | 2,536 | 4,503 | $886,558 | $234,041 |
| 2022 | 36 | 3,350 | 19,471 | $934,579 | $246,794 |
| 2021 | 40 | 4,528 | 32,276 | $990,687 | $266,203 |
| 2020 | 41 | 2,310 | 23,225 | $767,757 | $195,144 |
Total Patients
12,724
Total Services
79,475
Medicare Billing
$942,182
Procedure Codes
149
All Medicare Procedures & Services
149 procedure records from CMS Medicare Utilization — Page 1 of 6
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 419 | 1,184 | $426,390 | $88,967 | 20.9% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 382 | 382 | $142,404 | $47,311 | 33.2% |
| 99497 | Advance care planning, first 30 minutes | Office | 2023 | 342 | 343 | $81,625 | $25,957 | 31.8% |
| 91322 | Sarscov2 vac 50 mcg/0.5ml im | Office | 2023 | 63 | 63 | $22,050 | $9,009 | 40.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 119 | 162 | $41,310 | $8,299 | 20.1% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2023 | 111 | 111 | $9,100 | $7,067 | 77.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 48 | 52 | $26,364 | $5,989 | 22.7% |
| 90677 | Pneumococcal conjugate vaccine, 20 valent (pcv20), for intramuscular use | Office | 2023 | 17 | 17 | $8,500 | $4,804 | 56.5% |
| G0447 | Face-to-face behavioral counseling for obesity, 15 minutes | Office | 2023 | 156 | 168 | $12,430 | $4,098 | 33.0% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 74 | 96 | $18,507 | $3,786 | 20.5% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 123 | 125 | $7,500 | $3,693 | 49.2% |
| G0402 | Initial preventive physical examination; face-to-face visit, services limited to new beneficiary during the first 12 months of medicare enrollment | Office | 2023 | 21 | 21 | $9,791 | $3,329 | 34.0% |
| 99495 | Transitional care management services for problem of at least moderate complexity | Office | 2023 | 18 | 19 | $11,144 | $2,968 | 26.6% |
| G0438 | Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit | Office | 2023 | 16 | 16 | $7,603 | $2,531 | 33.3% |
| 20610 | Aspiration and/or injection of fluid from large joint | Office | 2023 | 36 | 61 | $11,221 | $2,495 | 22.2% |
| 90480 | Admn sarscov2 vacc 1 dose | Office | 2023 | 63 | 63 | $4,585 | $2,482 | 54.1% |
| G0444 | Annual depression screening, 5 to 15 minutes | Office | 2023 | 127 | 127 | $6,723 | $2,250 | 33.5% |
| 93793 | Anticoagulant management of patient taking warfarin | Office | 2023 | 27 | 229 | $7,508 | $1,714 | 22.8% |
| 87635 | Amplifed dna or rna probe detection of severe acute respiratory syndrome coronavirus 2 (covid-19) antigen | Office | 2023 | 25 | 26 | $1,300 | $1,274 | 98.0% |
| 85610 | Blood test, clotting time | Office | 2023 | 31 | 275 | $6,875 | $1,155 | 16.8% |
| 0134A | Adm sarscv2 bvl 50mcg/.5ml a | Office | 2023 | 25 | 25 | $1,850 | $984.75 | 53.2% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 45 | 226 | $4,294 | $935.07 | 21.8% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 28 | 71 | $3,390 | $531.16 | 15.7% |
| G0009 | Administration of pneumococcal vaccine | Office | 2023 | 15 | 15 | $900.00 | $443.10 | 49.2% |
| 93248 | Heart rhythm review and interpretation of continous external ekg over 8-15 days | Office | 2023 | 20 | 21 | $1,581 | $416.01 | 26.3% |
About Dr. Mark Silver, MD
Dr. Mark Silver, MD is a Ambulatory Family Planning Facility healthcare provider based in Brookings, Oregon. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/18/2005. The National Provider Identifier (NPI) number assigned to this provider is 1639178114.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mark Silver, MD has received a total of $5,774 in payments from pharmaceutical and medical device companies, with $293.91 received in 2024. These payments were reported across 305 transactions from 37 companies. The most common payment nature is "Food and Beverage" ($5,635).
As a Medicare-enrolled provider, Silver has provided services to 12,724 Medicare beneficiaries, totaling 79,475 services with total Medicare billing of $942,182. Data is available for 4 years (2020–2023), covering 149 distinct procedure/service records.
Ad
Practice Information
- Specialty Ambulatory Family Planning Facility
- Other Specialties Family Medicine
- Location Brookings, OR
- Active Since 07/18/2005
- Last Updated 04/10/2019
- Taxonomy Code 261QA0005X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1639178114
Products in Payments
- VRAYLAR (Drug) $561.34
- FARXIGA (Drug) $393.33
- ENTRESTO (Drug) $365.24
- ELIQUIS (Drug) $321.20
- XARELTO (Drug) $319.43
- JARDIANCE (Drug) $279.12
- INVOKANA (Drug) $272.55
- REXULTI (Drug) $222.66
- TROKENDI XR (Drug) $192.51
- Victoza (Drug) $158.98
- Ozempic (Drug) $148.00
- NATPARA (Drug) $139.04
- TRELEGY ELLIPTA (Drug) $133.36
- JANUVIA (Drug) $131.20
- TRULICITY (Drug) $130.90
- Xultophy 100/3.6 (Drug) $105.77
- SHINGRIX (Biological) $98.21
- EMGALITY (Drug) $82.99
- Tresiba (Drug) $70.00
- SYMBICORT (Drug) $62.35
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.